Technical analysis of BioNTech SE (BNTX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer.
Price Performance
| 1 month | -13.37% |
| 3 months | +5.69% |
| Year-to-date | +0.90% |
| 1 year | -0.17% |
| 3 years | -11.56% |
| 5 years | -71.66% |
52-Week Range
| 52-week High | $124.00 |
| 52-week Low | $79.52 |
| Avg Volume (90d) | 1.1M |
Technical Indicators
| SMA 50 | $97.13 |
| SMA 200 | $97.57 |
| Beta | 1.59 |
| 30-day Volatility (annualised) | 70.2% |
| Price vs SMA 50 | -1.1% |
| Price vs SMA 200 | -1.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $103.91 | |
| 2025-11 | $103.15 | -0.7% |
| 2025-12 | $95.20 | -7.7% |
| 2026-01 | $113.75 | +19.5% |
| 2026-02 | $110.23 | -3.1% |
| 2026-03 | $88.88 | -19.4% |
| 2026-04 | $103.45 | +16.4% |
| 2026-05 | $95.95 | -7.2% |
| 2026-06 | $93.05 | -3.0% |
| 2026-07 | $90.58 | -2.7% |
| 2026-08 | $101.61 | +12.2% |
| 2026-09 | $96.06 | -5.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-16 | | |
| 2026-09-16 | | $47M |
| 2026-09-16 | | $565M |
| 2026-09-16 | | |
| 2026-09-16 | $-0.72 | |
| 2026-09-16 | | $17M |
Price
| Price | $96.06 |
| Market Cap | $24.1B |
| Exchange | NASDAQ |
| Country | DE |
Valuation Ratios
| Price / Book | 1.18 |
| EV / EBITDA | -14.41 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 7.85 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 6.19 |